<DOC>
	<DOCNO>NCT02516124</DOCNO>
	<brief_summary>The purpose study assess effectiveness Autologous Hematopoietic Stem Cell transplantation ( AHSCT ) early severe rapidly progressive Systemic Sclerosis ( SSc ) currently perform different study protocol use across Europe various EBMT centre careful record analysis routinely collect clinical biological data .</brief_summary>
	<brief_title>EBMT ADWP Prospective Non Interventional Study : AutoHSCT SSc Patients</brief_title>
	<detailed_description>Different protocol use different centre , yet clear approach efficient safest . Every centre follow local protocol AHSCT usually refer recent update EBMT Guidelines HSCT autoimmune disease . Patient selection AHSCT treatment technique regard risk/benefit balance carefully addressed standard patient pretransplant evaluation , whereas treatment local regimen , follow-ups evaluation , supportive medication prophylaxis record analyse .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Autologous HSCT Age 18 65 year time transplant . Established diagnosis progressive systemic sclerosis accord ARAcriteria Pregnancy inadequate contraception Severe concomitant disease Reduced lung function Previously damage bone marrow Uncontrolled severe infection Severe concomitant psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Autoimmune disease</keyword>
	<keyword>Systemic sclerosis</keyword>
	<keyword>Autologous Hematopoietic stem cell transplant</keyword>
</DOC>